Table 1.

Descriptive characteristics for the studies included

Author, year	Population	Type of study	Follow-up (weeks)	Mean/median age (years)	Gestational age (weeks)	Number of vaccinated	Drug used as intervention	Dosage of the intervention drug (number-unit)	Quality of the studies (0–9)
Nasrallah, 2021 [20]	hospitalized women with moderate COVID-19	Prospective cohort	8	32 (range 16–44)	29.2	NR	Remdesivir	200 mg day 1 + 100 mg days 2–5	5
Kravchenko, 2021 [27]	hospitalized women with moderate COVID-19	Case–control study	NA	31.18 (range NA)	27.7	NA	IFN alpha 2b	3,000,000 UI rectal suppositories bid + 4000 UI gel five times/day on the nasal mucosa	6
Magawa, 2022 [29]	hospitalized women with moderate COVID-19	Retrospective cohort	0.7	30.25 (range 20–37)	28	0/8	Casirivimab/ imdevimab	600 mg/600 mg	7
Eid, 2022 [30]	non-hospitalized women with mild COVID-19	Retrospective cohort	NA	29.2 ± 8.2	26	43/115	Casirivimab/ imdevimab	NR	5
Valsecchi, 2022 [31]	hospitalized women with severe COVID-19	Retrospective cohort	4	30.3 ± 4.43	29.77	0/20	Nitric Oxide	200 ppm × 2	6
Tumash, 2022 [28]	hospitalized women with moderate COVID-19	Retrospective cohort	NA	33 (range NA)	32	NA	Remdesivir	200 mg day 1 + 100 mg days 2–5	5
Sinchikhin, 2022 [25]	non-hospitalized pregnant women exposed to COVID-19	Prospective cohort	3	25 (range NA)	NR	7/37	IFN alpha 2b	5000 ui	6
Levey, 2022 [32]	non-hospitalized pregnant women positive or exposed to COVID-19	Retrospective cohort	0	29.2 (range NA)	NR	0/36	Casirivimab/ imdevimab	600 mg/600 mg	5
Williams, 2022 [33]	non-hospitalized women with mild COVID-19	Retrospective cohort	NA	NA	NA	0/88	Casirivimab/ imdevimab	600 mg/600 mg	6
McCreary, 2022 [34]	non-hospitalized women with mild COVID-19	Retrospective cohort	4	30 (range 26- 33)	6	265/552	Bamlanivimab and etesevimab. casirivimab and imdevimab. or sotrovimab treatment compared with no mAb treatment	NA	7

NA: not applicable, NR: not reported